Study guide

1.3 Heart Failure & Cardiomyopathy

NCCPA PANCE Physician Assistant Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Cardiovascular System

1.1 Hypertension (Essential & Secondary) 1.2 Coronary Artery Disease & Myocardial Infarction 1.3 Heart Failure & Cardiomyopathy 1.4 Cardiac Arrhythmias & Conduction Disorders 1.5 Valvular Heart Disease 1.6 Vascular Diseases (Aortic Aneurysm, PAD, DVT) 1.7 Congenital Heart Disease (ASD, VSD, PDA, Coarctation, Tetralogy of Fallot)

2 Chapter 2: Pulmonary System

Section 2.1: Asthma & Bronchospastic Disease Section 2.2: Chronic Obstructive Pulmonary Disease (COPD) Section 2.3: Infectious Pulmonary Disorders (Pneumonia & Tuberculosis) Section 2.4: Restrictive, Vascular & Neoplastic Pulmonary Conditions

3 Chapter 3: Gastrointestinal/Nutrition

3.1 Esophageal & Gastric Disorders (GERD, PUD) 3.2 Hepatic, Biliary & Pancreatic Disorders 3.3 Small & Large Bowel Disorders (IBD, Diverticulitis, Obstruction) 3.4 Colorectal Neoplasms & Nutritional Deficiencies

4 Chapter 4: Musculoskeletal System

Section 4.1: Rheumatologic & Autoimmune MSK Conditions (RA, Lupus, Gout, OA) Section 4.2: Infectious & Inflammatory MSK Disorders (Osteomyelitis, Septic Arthritis) Section 4.3: Bone & Joint Disorders (Fractures, Osteoporosis, Fibromyalgia) Section 4.4: Spine and Soft Tissue Pathology (Low Back Pain, Tendonitis)

5 Chapter 5: Neurologic System

Section 5.1: Cerebrovascular Disease (Stroke, TIA) Section 5.2: Seizure Disorders & Epilepsy Section 5.3: Demyelinating & Neurodegenerative Diseases Section 5.4: Headache Syndromes & Cranial Nerve Disorders

6 Chapter 6: Psychiatry/Behavioral Science

Section 6.1: Depressive and Bipolar Disorders Section 6.2: Anxiety, Trauma-Related, and Obsessive-Compulsive Disorders Section 6.3: Schizophrenia and Psychotic Disorders Section 6.4: Eating, Substance Use, and Personality Disorders

7 Chapter 7: Infectious Diseases

7.1 Viral Infections (HIV, EBV, Influenza) 7.2 Bacterial & Spirochetal Infections (Sepsis, Meningitis) 7.3 Fungal & Parasitic Infections 7.4 Tick-Borne Diseases (Lyme, Rocky Mountain Spotted Fever)

8 Chapter 8: Reproductive System

8.1 Obstetrics: Normal Pregnancy & Prenatal Care 8.2 Obstetrics: Pregnancy Complications 8.3 Gynecology: Menstruation, Menopause, PCOS, and Vaginal Infections

9 Chapter 9: Endocrine System

Section 9.1: Diabetes Mellitus & Acute Complications Section 9.2: Thyroid Disorders & Goiter Section 9.3: Adrenal & Pituitary Disorders

10 Chapter 10: Eyes, Ears, Nose, and Throat

Section 10.1: Ophthalmic Disorders (Glaucoma, Conjunctivitis, Cataracts) Section 10.2: Otic Disorders (Otitis Media/Externa, Vertigo, Labyrinthitis) Section 10.3: Nose, Sinus, and Throat Complaints (Sinusitis, Pharyngitis, Epiglottitis)

11 Chapter 11: Professional Practice

11.1 Bioethics & Legal Standards (Informed Consent, Autonomy, HIPAA) 11.2 Patient Safety, Quality Improvement, and Communication 11.3 Evidence-Based Medicine & Clinical Practice Guidelines

12 Chapter 12: Hematologic System

Section 12.1: Anemias (Microcytic, Macrocytic, Hemolytic/Sickle Cell) Section 12.2: Coagulation and Bleeding Disorders (ITP, TTP, Hemophilia, vWD) Section 12.3: Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)

13 Chapter 13: Renal System

13.1 Acute Kidney Injury (AKI) & Chronic Kidney Disease (CKD) 13.2 Acid-Base and Electrolyte Disorders 13.3 Glomerular & Tubulointerstitial Diseases

14 Chapter 14: Dermatologic System

Section 14.1: Inflammatory & Autoimmune Skin Conditions Section 14.2: Infectious Skin Conditions Section 14.3: Skin Neoplasms & Burn Management

15 Chapter 15: Genitourinary System

Section 15.1: Male Genitourinary Disorders (BPH, Prostate Cancer, Testicular Torsion, ED) Section 15.2: Urinary Incontinence, Nephrolithiasis, and GU Trauma

1.3 Heart Failure & Cardiomyopathy

Key Takeaways Explain This Topic AI

HFrEF is defined by EF <=40% and associated with an S3 gallop, while HFpEF is defined by EF >=50% and associated with an S4 gallop.

Four pillars of GDMT that improve survival in HFrEF: ARNI (Sacubitril/Valsartan), selected Beta-blockers, Aldosterone Antagonists, and SGLT2 inhibitors.

A 36-hour washout period is required when transitioning from an ACE inhibitor to Sacubitril/Valsartan to avoid bradykinin-mediated angioedema.

Hypertrophic cardiomyopathy (HCM) presents with asymmetrical septal hypertrophy; dynamic murmur increases with Valsalva/standing and decreases with squatting/handgrip.

Restrictive cardiomyopathy presents with rigid ventricles and biatrial enlargement; amyloidosis is the most common cause (apple-green birefringence).

Last updated: July 2026

Heart Failure & Cardiomyopathy

PANCE High-Yield Focus: Heart failure is heavily tested on the PANCE, particularly the pharmacological management of systolic heart failure. Memorize the four pillars of Guideline-Directed Medical Therapy (GDMT) that provide a mortality benefit in HFrEF. Be prepared to identify the physical exam signs of heart failure (such as S3 and S4 gallops) and the distinct clinical presentations, dynamic murmur changes, and diagnostic profiles of dilated, hypertrophic, and restrictive cardiomyopathies.

Heart Failure Classifications & Pathophysiology

Heart failure is a complex clinical syndrome resulting from any structural or functional impairment of ventricular filling or ejection of blood.

Heart Failure with Reduced Ejection Fraction (HFrEF / Systolic HF): Defined by an ejection fraction (EF) <=40% . It is characterized by inadequate myocardial contractility, leading to eccentric ventricular remodeling. Common etiologies include ischemic heart disease (post-MI), dilated cardiomyopathy, and chronic volume overload.

Heart Failure with Preserved Ejection Fraction (HFpEF / Diastolic HF): Defined by an ejection fraction (EF) >=50% . It is characterized by impaired ventricular relaxation and decreased compliance during diastole, preventing proper filling. Common etiologies include concentric ventricular hypertrophy (driven by long-standing hypertension), restrictive cardiomyopathy, and aging.

ACC/AHA Stages vs. NYHA Functional Classes

ACC/AHA Stages (Progressive, objective staging - Patients cannot move backward):

Stage A: High risk for heart failure but no structural heart disease or symptoms.

Stage B: Structural heart disease present, but without symptoms of heart failure (e.g., asymptomatic low EF).

Stage C: Structural heart disease with current or prior symptoms of heart failure.

Stage D: Advanced refractory heart failure requiring specialized interventions (e.g., transplant, LVAD, continuous inotropes).

NYHA Functional Classes (Symptom-based classification - Can change dynamically with therapy):

Class I: No limitation of physical activity.

Class II: Slight limitation. Comfortable at rest, but ordinary activity causes dyspnea, fatigue, or palpitations.

Class III: Marked limitation. Comfortable at rest, but less-than-ordinary activity causes symptoms.

Class IV: Inability to carry out physical activity without discomfort; symptoms may be present at rest.

Diagnostic Workup of Heart Failure

A comprehensive workup combines biomarkers, imaging, and clinical evaluation:

B-type Natriuretic Peptide (BNP) and NT-proBNP: Released by ventricles in response to increased wall stretch and volume overload. Highly useful for differentiating cardiac dyspnea from pulmonary dyspnea in acute settings. PANCE Tip: BNP levels can be falsely elevated in renal failure (due to decreased clearance) and falsely low in obese patients.

Echocardiography: The single most useful diagnostic tool. It establishes the ejection fraction, evaluates chamber sizes, wall thickness, valvular function, and diastolic filling parameters.

Clinical Auscultation:

S3 Gallop: Low-pitched diastolic sound occurring during rapid passive ventricular filling. Pathognomonic for systolic heart failure (HFrEF) , reflecting a large volume of blood filling a dilated, compliant ventricle.

S4 Gallop: Low-pitched late diastolic sound occurring during active atrial contraction. Pathognomonic for diastolic heart failure (HFpEF) , reflecting atrial contraction against a stiff, non-compliant ventricle.

Guideline-Directed Medical Therapy (GDMT) for HFrEF

Pharmacotherapy for HFrEF is focused on blocking chronic neurohumoral overactivation (the sympathetic nervous system and RAAS) that drives adverse ventricular remodeling. Four drug classes make up the "four pillars" of GDMT that reduce mortality :

Angiotensin Receptor-Neprilysin Inhibitor (ARNI): Sacubitril/Valsartan is preferred over ACEi or ARBs. Sacubitril inhibits neprilysin, preventing the breakdown of beneficial natriuretic peptides (which promote vasodilation and natriuresis), while Valsartan blocks the AT1 receptor.

Clinical Rule: A 36-hour washout period is mandatory when switching from an ACEi to an ARNI to prevent life-threatening angioedema. A washout is not required when transitioning from an ARB.

Beta-blockers: Only three beta-blockers have a proven mortality benefit in HFrEF: Carvedilol, Metoprolol succinate (long-acting), and Bisoprolol . PANCE Warning: Do not start or titrate beta-blockers in patients with acute decompensated heart failure (fluid overload). The patient must be hemodynamically stable and dry first.

Aldosterone Antagonists (Spironolactone or Eplerenone): Indicated for patients with NYHA Class II-IV and EF <=35%. They reduce cardiac fibrosis. Monitor potassium and renal function closely ; contraindicated if K+ > 5.0 mEq/L or creatinine >2.5 mg/dL (men) / >2.0 mg/dL (women).

SGLT2 Inhibitors (Dapagliflozin or Empagliflozin): Originally developed for diabetes, these agents reduce cardiovascular mortality and heart failure hospitalizations in HFrEF, regardless of glycemic status.

Symptomatic Control: Loop Diuretics (Furosemide, Bumetanide) are the cornerstone for managing volume overload and congestion (pulmonary rales, peripheral edema). They improve symptoms but do not provide a mortality benefit .

Cardiomyopathy Types

Cardiomyopathies are diseases of the heart muscle that cause mechanical or electrical dysfunction.

Cardiomyopathy Type Pathophysiology Common Etiologies Clinical & Diagnostic Findings First-Line Management

Dilated Impaired systolic contraction; eccentric hypertrophy (dilated ventricles) Idiopathic, alcohol abuse, cocaine, viral myocarditis (Coxsackie B), Doxorubicin chemotherapy, pregnancy S3 gallop, balloon-like heart on Chest X-ray, low ejection fraction on Echo Standard HFrEF GDMT (ARNI, Beta-blocker, Aldosterone antagonist, SGLT2i)

Hypertrophic (HCM) Asymmetrical septal hypertrophy; dynamic left ventricular outflow tract (LVOT) obstruction Genetic mutation in sarcomere proteins (autosomal dominant) Harsh systolic crescendo-decrescendo murmur at LLSB that increases with Valsalva/standing and decreases with squatting/handgrip . Can cause sudden cardiac death in young athletes Beta-blockers (slows heart rate, increases diastolic filling time, reduces obstruction). Avoid vasodilators, diuretics, and digoxin

Restrictive Rigid ventricles with impaired diastolic filling; normal systolic function Amyloidosis (most common), sarcoidosis, hemochromatosis, radiation fibrosis Right-sided heart failure findings (JVD, hepatomegaly, ascites). ECG may show low voltage. Echo reveals biatrial enlargement with normal ventricles. Biopsy showing amyloid (apple-green birefringence under polarized light) Treatment of the underlying cause; cautious use of low-dose diuretics for congestion

PANCE Clinical Traps

HCM Murmur Differentiation: The murmur of HCM sounds identical to Aortic Stenosis (AS). Differentiate them using dynamic auscultation:

Valsalva/Standing: Decreases preload. This increases the HCM murmur (a smaller LV chamber allows the septum and mitral leaflet to come closer, increasing outflow obstruction) but decreases the AS murmur (less volume passing through a fixed stenotic valve).

Squatting/Passive Leg Raise: Increases preload. This decreases the HCM murmur (larger LV chamber pushes the septum away from the mitral leaflet, reducing obstruction) but increases the AS murmur (more blood volume across the valve).

Avoid in Severe HCM: Never prescribe diuretics, nitrates, CCBs (dihydropyridines), or digoxin in patients with obstructive HCM. Diuretics and nitrates decrease preload, which worsens LVOT obstruction, while digoxin increases contractility, bringing the septum closer to the valve and worsening the blockage.